Review

Vitamin D and Human Skeletal Muscle

B. Hamilton

ASPETAR, Qatar Orthopaedic and Sports Medicine Hospital, Doha, Qatar

Corresponding author: Bruce Hamilton, ASPETAR, Qatar Orthopaedic and Sports Medicine Hospital, PO Box 29222, Doha, Qatar. Tel: +974 413 2000, Fax: +974 413 2027, E-mail: bruce.hamilton@aspetar.com

Accepted for publication 8 July 2009

Vitamin D deficiency is an increasingly described phenomenon worldwide, with well-known impacts on calcium metabolism and bone health. Vitamin D has also been associated with chronic health problems such as bowel and colonic cancer, arthritis, diabetes and cardiovascular disease. In recent decades, there has been increased awareness of the impact of vitamin D on muscle morphology and function, but this is not well recognized in the Sports Medicine literature. In the early 20th century, athletes and coaches felt that ultraviolet rays had a positive impact on athletic performance, and increasingly, evidence is accumulating to support this view. Both cross-sectional and longitudinal studies allude to a functional role for vitamin D in muscle and more recently the discovery of the vitamin D receptor in muscle tissue provides a mechanistic understanding of the function of vitamin D within muscle. The identification of broad genomic and non-genomic roles for vitamin D within skeletal muscle has highlighted the potential impact vitamin D deficiency may have on both under-performance and the risk of injury in athletes. This review describes the current understanding of the role vitamin D plays within skeletal muscle tissue.

Vitamin D is a secosteroid produced in the skin, under the influence of ultraviolet-B (UVB) radiation converting 7-dehydrocholesterol to pre-vitamin D3. In the dermis, pre-vitamin D3 is rapidly converted to vitamin D3 (cholecalciferol), before its subsequent conversion to 25-hydroxy vitamin D (25(OH)D) in the liver. Further hydroxylation of 25-hydroxy vitamin D to its active form, 1,25 hydroxy vitamin D (1,25(OH)2D), occurs in the kidney (Holick, 2007). Lesser quantities are also found in the diet in the form of vitamin D2 (ergocalciferol), which undergoes the same hydroxylation process. Vitamin D is transported in the blood, bound to vitamin D binding protein.

Vitamin D is well recognized for its role in calcium and phosphorus homeostasis. In conjunction with parathyroid hormone (PTH), vitamin D plays a critical role in calcium homeostasis (Cashman, 2007), and as a result, vitamin D deficiency has been implicated in osteoporotic and stress-related fractures (Ruoohala et al., 2006; Lappe et al., 2007, 2008). Less well recognized are its genomic and non-genomic roles in other tissues (Holick, 2006), despite cross-sectional data linking vitamin D deficiency to bowel and colonic cancer, arthritis, diabetes and cardiovascular disease (Pani et al., 2000; Hypponen et al., 2001, 2008; Dietrich et al., 2004; Holick, 2004, 2006, 2007; Garland et al., 2006; Giovannucci et al., 2006; Lappe et al., 2007; Pittas et al., 2007).

Both the definition of vitamin D deficiency and what constitutes an appropriate supplementation strategy continue to be debated (Malabanan et al., 1998; Dawson-Hughes et al., 2005; Bischoff-Ferrari et al., 2006; Bischoff-Ferrari & Dawson-Hughes, 2007; Hansen et al., 2008). While 1,25(OH)2D is the active form of vitamin D, 25(OH)D is the appropriate index for estimating whole-body vitamin D levels. This is the result of both its substantially higher concentration and the fact that even with a marked vitamin D deficiency, elevated PTH levels will maintain the conversion of 25(OH)D to 1,25(OH)2D, thereby sustaining 1,25(OH)2D levels within normal ranges, despite low reserves (Holick, 2004). It is generally accepted that 25(OH)D levels of 20–30 ng/mL (ng/mL × 2.5 = nmol/L) represent insufficiency, while levels below 20 and 10 ng/mL represent deficiency and severe deficiency, respectively (Holick, 2007). Recent evidence suggests that inter-laboratory variability in 25(OH)D assessment may also complicate the interpretation of vitamin D deficiency (Binkley et al., 2004).

Notwithstanding these issues, vitamin D deficiency is increasingly being recognized as a worldwide epidemic (Nowson & Margerison, 2002; Gordon et al., 2004; Hashemipour et al., 2004; Andersen et al., 2005; Rockell et al., 2005; Binkley et al., 2007; Hannan et al., 2008). With the most common
cause of vitamin D deficiency being inadequate sunlight exposure, it is not surprising that higher latitude countries have a high incidence of deficiency (Andersen et al., 2005). However, despite its high sunlight hours, vitamin D deficiency is well recognized in Middle Eastern women (Fonseca et al., 1984; Hatun et al., 2005; Allali et al., 2006), and more recently in inner city young adults in America (Gordon et al., 2004), elite gymnasts in Australia (Lovell, 2008), young Hawaiian skateboarders (Binkley et al., 2007), and adolescent girls in England (Ward et al., 2009). Vitamin D deficiency may have significant long-term health impacts (Holick, 2004; Giovannucci et al., 2006), but it is also possible that a deficiency will result in more immediate effects on musculoskeletal health, with an increased risk of injuries such as stress fractures (Ruohola et al., 2006; Lapte et al., 2007, 2008). While there is no evidence to support or refute the possibility that vitamin D deficiency will affect the injury profile of tissues such as muscle, the evidence presented herein suggests that further research in this area is required. Furthermore, little is known of any performance impact of vitamin D deficiency; however, some authors suspect it may be a marked impediment to performance when not available in adequate levels (Cannell et al., 2009). Indeed, in the early part of the 20th century, athletes were allegedly using UVB rays as an ergogenic aid (Hoberman, 1992; Cannell et al., 2009) and research over that period suggested that both cardiovascular fitness and muscular endurance were enhanced with exposure to ultraviolet radiation (Allen & Cureton, 1945). While vitamin D deficiency has long been associated with muscle weakness (Floyd et al., 1974; Irani, 1976; Russell, 1994; Ceglia, 2008), until recently no specific etiological mechanism had been described. Over the last 30 years, an independent mechanism for vitamin D and muscle function has slowly been unraveled. Subsequently, while limited, there is evidence from a range of sources relating vitamin D deficiency to suboptimal muscle function. This review aims to describe the available evidence for a role of vitamin D in muscle function, and thereby its potential impact on the athletic individual.

Myopathy associated with vitamin D deficiency

Myopathy associated with vitamin D deficient osteomalacia has been recognized for many years, presenting predominantly as a proximal muscle weakness or difficulty in walking upstairs (Floyd et al., 1974; Irani, 1976; Russell, 1994; Ceglia, 2008). Traditionally, it was felt that this myopathic presentation was secondary to osteomalacia and disise, rather than a direct effect of vitamin D on muscle; however, the increased mechanistic under-

standing of vitamin D challenges this presumption (Glerup et al., 2000). As early as 1974, authors had illustrated electromyographic changes in patients with muscle weakness associated with osteomalacia (Floyd et al., 1974), which improved with vitamin D supplementation (Irani, 1976). Subsequently, numerous reports attest to the reversibility of the myopathy associated with vitamin D deficiency (Rimaniol et al., 1994; Russell, 1994; Ziambaras & Dagogo-Jack, 1997; Mingrone et al., 1999; Prabhala et al., 2000).

Glerup et al. (2000) examined the impact of vitamin D supplementation on vitamin D-associated myopathy. In a preliminary study, a small group (n = 8) of elderly men and women (mean age 63.1 ± 5.3 years) with known osteomalacia had muscle strength assessed using an isokinetic dynamometer before and after 3 months of treatment with alfalcacidol, ergocalciferol and calcium. They found that over 3 months, muscle power increased significantly in all the muscle groups assessed, with a mean improvement of 24.8 ± 8.0%. Subsequently, they compared a group of vitamin D-deficient Arab women with a control group of Danish women with normal levels of vitamin D. At baseline, quadriceps maximum voluntary contraction (MVC), as well as electrically stimulated twitch [single twitch, maximum production rate (MPR) and maximal relaxation rate (MRR)], were all significantly lower in the Arab women. Three months of vitamin D supplementation, without strength training, increased vitamin D levels and normalized PTH levels in the Arab women, with a corresponding trend toward normalization of the MVC, MPR and MRR. Multivariate regression analysis revealed that only 25(OH)D was significantly associated with MVC. Given that there was no correlation between muscle power and markers of osteomalacia, the authors concluded that normal levels of 25(OH)D are necessary for maintaining adequate muscle function.

Morphology

Early biopsy studies (Floyd et al., 1974; Irani, 1976), and subsequent case reports of the muscle weakness associated with osteomalacia (Russell, 1994; Ziambaras & Dagogo-Jack, 1997), have revealed either non-specific or type II muscle fiber atrophy. Sato et al. (2005) were the first to assess the impact of vitamin D supplementation on muscle histopathology. They biopsied the non-hemiplegic vastus lateralis of 85 vitamin D-deficient elderly stroke patients, before and after a 2-year supplementation period with either placebo or vitamin D2. At baseline they found a normal range of type I fibers, but a reduced
proportion and diameter of type II muscle fibers. At the 2-year follow-up, the placebo group showed a further reduction in type II muscle fiber diameter, while in the vitamin D2-supplemented group the relative content and mean diameter of type II fibers increased, with the fiber size correlating with 25(OH)D levels (Sato et al., 2005).

Age-related changes in muscle function

It is well recognized that muscle strength declines with age, due to a number of contributory factors (Iannuzzi-Sucich et al., 2002). However, the role of vitamin D in any age-related strength decline continues to be debated (Janssen et al., 2002; Latham et al., 2003a,b), with the majority of studies being cross-sectional in design (Bischoff et al., 1999; Mowe et al., 1999; Bischoff-Ferrari et al., 2004a,c; Houston et al., 2007; Wicherts et al., 2007). These studies appear to show a relationship between 25(OH)D levels and various measures of changes in muscle strength and function with aging (Bischoff et al., 1999; Mowe et al., 1999; Bischoff-Ferrari et al., 2004a,c; Houston et al., 2007; Wicherts et al., 2007). By contrast, a review of randomized-controlled trials investigating vitamin D and/or calcium supplementation concluded that while a combination of calcium and vitamin D may improve physical function and reduce falls, there was no evidence that vitamin D alone improved the strength or the physical function of elderly people (Latham et al., 2003a,b). Increasingly, however, well-controlled and designed studies support a role for vitamin D in moderating the age-related decline in muscle function (Bischoff et al., 2003; Visser et al., 2003; Gerdhem et al., 2005), with a potential mechanism described recently (Bischoff-Ferrari et al., 2004a,c; Roth et al., 2004).

For example, Visser et al. (2003) prospectively investigated the impact of low 25(OH)D and high serum PTH in 1008 men and women aged over 65 years (mean 74 years) and found that individuals with a lower 25(OH)D and/or higher PTH levels were significantly more likely to lose grip strength and muscle mass. They also found 25(OH)D levels of 30 ng/mL to be a threshold for optimal muscle function. In the same year, Bischoff et al (2003) performed a 12-week double-blind, randomized-controlled trial utilizing vitamin D and calcium vs calcium supplementation alone. They reported a significant improvement in knee flexor and extensor strength, grip strength and functional (timed up and go) testing, in their elderly group following vitamin D and calcium, vs calcium supplementation alone. Further, Gerdhem et al. (2005), in a 3-year study of 986 Swedish 75-year-old women, found that reduced 25(OH)D levels correlated with reduced gait speed, reduced knee flexor and extensor strength and increased risk of falls. Similarly, Broe et al. (2007), in a 5-month prospective randomized-controlled trial, illustrated a dose-dependent (800 IU/day) impact of vitamin D supplementation on significantly reducing falls in the elderly. Several other prospective studies have reported similar functional benefits (Verhaar et al., 2000; Dhesi et al., 2004; Sato et al., 2005; Bunout et al., 2006) and a meta-analysis of studies has confirmed the benefit of vitamin D supplementation on fall prevention (Bischoff-Ferrari et al., 2004b).

By contrast, in a large prospective randomized-controlled trial, Latham et al. (2003a,b) assessed the relative benefits of home resistance exercise or a single high dose of vitamin D, on self-reported physical health, risk of falls and functional performance at 3 and 6 months. Despite increasing the serum 25(OH)D level in those individuals treated, they found no significant impact of 25(OH)D on any of the functional outcome parameters (Latham et al., 2003a,b).

In an effort to evaluate a potential mechanism of vitamin D-associated changes in muscle morphology and function with age, the expression of the vitamin D Receptor (VDR) was assessed in the gluteus medius and transversospinalis muscles of female patients undergoing hip arthroplasty and spinal operations, respectively (Bischoff-Ferrari et al., 2004a,c). The authors found that VDR expression decreased with age and that VDR expression was unaffected by either 25(OH)D or 1,25(OH)2D levels. The authors suggested that age-related decline in muscle strength may be related to reduced VDR expression. Furthermore, VDR polymorphisms may also result in variable susceptibility to age-related sarcopenia (Roth et al., 2004).

By far the majority of vitamin D studies have been performed on the elderly population, who are prone to sarcopenia, and as a result there is limited evidence for the impact of vitamin D on healthy young individuals. However, El-Hajj et al. (2006) reported a 1-year prospective double-blind, placebo-controlled trial of low- and high-dose vitamin D3 in 179 adolescent Lebanese girls. In vitamin D-supplemented individuals they found increased lean mass, bone area and bone mass, particularly in pre-menarchal girls, but found no increase in grip strength. Furthermore, there were no significant findings regarding 25(OH)D and muscle mass or grip strength in a similar cohort of male adolescents (El-Hajj et al., 2006). By contrast, a recent study of 99 post-menarchal adolescent girls in England found a positive relationship between serum 25(OH)D level and jump height, jump velocity and power (Ward et al., 2009).
Vitamin D and muscle function: mechanistic considerations

The VDR

Attempts to identify an independent role for vitamin D on skeletal muscle began in earnest in 1975 when 25(OH)D, presumably via a specific receptor, was proposed to directly stimulate the synthesis of protein, ATP and inorganic phosphate in the rat diaphragm muscle (Birge & Haddad, 1975). However, there continued to be some debate as to whether or not vitamin D has a truly independent effect on muscle. Wassner et al. (1983) discredited the aforementioned study, and concluded that vitamin D has no direct effect on muscle, rather its impact was felt to be indirect, via calcium and insulin (Wassner et al., 1983). This debate was settled in 1985 when a VDR was recognized within cultured rat myoblast cells, thereby showing that muscle is a direct target organ for 1,25(OH)2D (Simpson et al., 1985). The VDR has subsequently been described in tissues such as smooth muscle, heart muscle, liver, lung, colon, gonads and skin (Pfiefer et al., 2002; Nibbelink et al., 2007), and was recently isolated from human skeletal muscle (Bischoff et al., 2001; Bischoff-Ferrari et al., 2004a, c).

1,25(OH)2D receptors have been characterized as members of the steroid hormone super-family, acting as a hormone-inducible transcription factor (Peng et al., 2004; Liao et al., 2008). Furthermore, VDR have been shown to have various genetic polymorphisms, which may affect their function within skeletal muscle (Geusens et al., 1997; Grundberg et al., 2004; Hopkinson et al., 2008). In combination with co-factors “retinoid × receptor” and “Steroid Receptor Coactivator 3” (SRC), the VDR: 1,25(OH)2D complex modulates gene expression of a number of proteins, via binding to specific target gene promoter regions, known as “vitamin D response elements” (VDRE) (Peng et al., 2004; Liao et al., 2008). This may include both proteins with roles in calcium metabolism such as calbindin (Fleet, 2004), but also proteins not directly related to calcium metabolism such as insulin-like growth factor binding protein 3 (IGFBP-3) (Peng et al., 2004).

To assess the role of the VDR in the skeletal muscle of mice, a generation of VDR gene-deleted mice and myoblast cell lines were examined (Endo et al., 2003). In order to exclude the impact of secondary metabolic abnormalities such as hypocalcemia, gene-deplete mice were assessed at 3 weeks, before weaning and development of secondary metabolic problems. Analysis revealed that VDR null mice had fiber sizes in the quadriceps and other muscle groups 20% smaller than VDR-replete mice and that this trend progressed as secondary metabolic factors developed from 3 weeks of age. Furthermore, VDR null mice exhibited increased expression of myogenic transcription factors myf5, E2A and myogenin compared with normal mice along with inappropriate expression of embryonic and neonatal type myosin heavy chain (Endo et al., 2003). These findings support a direct role for 1,25(OH)2D and the VDR in both the metabolic processes and the transcriptional regulation of skeletal muscle. Subsequently, it is likely that 1,25(OH)2D and the VDR influence skeletal muscle via both genomic and nongenomic mechanisms (Schmidt et al., 2000; Nguyen et al., 2004).

Genomic actions of vitamin D

Typical of steroid hormones, the binding of 1,25(OH)2D to the VDR results in enhanced transcription of a range of proteins, including those involved in calcium metabolism (Fleet, 2004). Calcium is a critical modulator of skeletal muscle function and any perturbation to calcium handling may impact on both its contractile and relaxation properties (Berkthold et al., 2000). Therefore, 1,25(OH)2D may affect muscle function through both calcium-related protein transcription and total body calcium levels. Recently, however, it has transpired that 1,25(OH)2D also has a transcription-enhancing role on proteins other than those involved directly in calcium metabolism. One such protein, relevant to the discussion of skeletal muscle, is IGFBP-3. In order to illustrate the potential impact of 1,25(OH)2D on skeletal muscle function, the role of insulin-like growth factor-1 (IGF-1) and IGFBP-3 will be described in further detail.

IGF-1 is a 7.5 kDa polypeptide, structurally similar to insulin (Thissen et al., 1994). It induces proliferation, differentiation and hypertrophy of skeletal muscle (Barton-Davis et al., 1998) and is a key component in muscle regeneration (Schertzer et al., 2007). IGF-1 has at least three isoforms resulting from splice variations, namely IGF-1Ea, IGF-1Eb and IGF-1Ec (Goldspink, 2005). IGF-1Ea is the circulating form of IGF-1 expressed from the liver, whereas IGF-1Ec, also known as mechano-growth factor (MGF), is the tissue isoform released from skeletal muscle cells, believed to exert exclusively autocrine/paracrine actions (Goldspink, 1999). Each isoform may have slightly different biological actions, with IGF-1Ea stimulating terminal differentiation of muscle cells into myotubes and promoting stem-cell mediated muscle regeneration. By contrast, MGF responds to tissue damage, controls local tissue repair and is more potent than IGF-1Ea at causing hypertrophy (Goldspink, 1999). Subsequently, IGF-1 is recognized as both a potential means for addressing age-related sarcopenia (Grounds, 2002) and as an illegal ergogenic aid in...
IGF-1 circulates in the serum 99% bound to a carrier protein IGFBP-3. Only 1% of serum IGF-1 is “free” (fIGF-1) to exert the biological effects, and when unbound, IGF-1 is rapidly cleared (Liao et al., 2008).

IGFBP-3 is a member of the IGFBP family, which bind IGF-1 in the serum, the extracellular matrix or on cell surfaces (Berg et al., 2007) with high affinity and specificity (Baxter, 2000; Peng et al., 2004). The binding of IGF-1 to IGFBP’s may have both inhibitory and stimulatory effects on IGF-1 function (Baxter, 2000). The IGF-1–IGFBP-3 complex may block the binding of IGF-1 to its receptors, thereby mitigating its effect on DNA synthesis, growth and glucose regulation (Baxter, 2000), but preventing its otherwise rapid clearance (Liao et al., 2008). Furthermore, presumably as a result of increased free IGF-1, the inhibition of IGF-1 binding to IGF-1BP has been shown to enhance the healing of mice skeletal muscle (Schertzer et al., 2007). It has also been suggested that IGFBP may have a role independent of any IGF-1 binding, inhibiting both DNA synthesis and inducing apoptosis (Baxter, 2000; Peng et al., 2004).

IGFBP-3 expression is regulated by a number of factors, including 1,25(OH)2D (Peng et al., 2004), with a VDRE in the promoter region for human IGFBP-3 recently identified (Peng et al., 2004). Thus, 1,25(OH)2D, in combination with the VDR and other elements, such as SRC-3 (Liao et al., 2008), can positively influence IGFBP-3 expression (Fig. 1). For example, without SRC-3 cofactor combination with the activated VDR, transcriptional expression of IGFBP-3 is reduced, and as a result IGF-1 clearance is increased (Liao et al., 2008).

The potential significance of this process involving IGF-1 was illustrated in a recent investigation of children with vitamin D-deficient rickets, before and after supplementation with vitamin D (Soliman et al., 2008). The authors found that the growth rates and height of the children increased with vitamin D supplementation, and that there was a significant correlation between serum concentrations of IGF-1 and the percentage increment in 25(OH)D concentrations, with IGF-1 concentrations increasing significantly after treatment with vitamin D. Both the length and the growth rate correlated with the IGF-1 concentration, leading the authors to conclude that the growth spurt observed in children with rickets after vitamin D supplementation is mediated via an increase in IGF-1 (Soliman et al., 2008).

VDR polymorphisms and skeletal muscle function

The VDR gene located on chromosome 12 (12q13.11) (Bray et al., 2009) is known to have various genetic polymorphisms including Bsm1, Fok1, Apal and Taq1, which have been associated with various functional outcomes (Geusens et al., 1997; Roth et al., 2004; Hopkinson et al., 2008). The Fok1 polymorphism involves a T to C transition in exon 2 of the VDR gene, resulting in a shorter (424) amino acid VDR than the T allele (427) (Guo et al., 2006), and has been associated with variations in both bone mineral density (Zhang et al., 2008) and differential responses of bone density to strength training (Tajima et al., 2000; Rabon-Stith et al., 2005). Furthermore, an association with fat-free mass and risk of age-related sacroplenia has been described (Roth et al., 2004) and in patients suffering from chronic obstructive pulmonary disease (COPD), Fok1 C homozygotes (also known as FF) were found to have significantly weaker quadriceps than either CT heterozygotes or T (ff) homozygotes (Hopkinson et al., 2008).

Geusens et al. (1997) assessed the impact of VDR polymorphisms on grip and quadriceps strength. Five hundred and one healthy women over the age of 70 were assessed for quadriceps and grip strength and after supplementation with vitamin D (Soliman et al., 2008). The authors found that the growth rates and height of the children increased with vitamin D supplementation, and that there was a significant correlation between serum concentrations of IGF-1 and the percentage increment in 25(OH)D concentrations, with IGF-1 concentrations increasing significantly after treatment with vitamin D. Both the length and the growth rate correlated with the IGF-1 concentration, leading the authors to conclude that the growth spurt observed in children with rickets after vitamin D supplementation is mediated via an increase in IGF-1 (Soliman et al., 2008).

VDR polymorphisms and skeletal muscle function

The VDR gene located on chromosome 12 (12q13.11) (Bray et al., 2009) is known to have various genetic polymorphisms including Bsm1, Fok1, Apal and Taq1, which have been associated with various functional outcomes (Geusens et al., 1997; Roth et al., 2004; Hopkinson et al., 2008). The Fok1 polymorphism involves a T to C transition in exon 2 of the VDR gene, resulting in a shorter (424) amino acid VDR than the T allele (427) (Guo et al., 2006), and has been associated with variations in both bone mineral density (Zhang et al., 2008) and differential responses of bone density to strength training (Tajima et al., 2000; Rabon-Stith et al., 2005). Furthermore, an association with fat-free mass and risk of age-related sacroplenia has been described (Roth et al., 2004) and in patients suffering from chronic obstructive pulmonary disease (COPD), Fok1 C homozygotes (also known as FF) were found to have significantly weaker quadriceps than either CT heterozygotes or T (ff) homozygotes (Hopkinson et al., 2008).

Geusens et al. (1997) assessed the impact of VDR polymorphisms on grip and quadriceps strength. Five hundred and one healthy women over the age of 70 were assessed for quadriceps and grip strength and after supplementation with vitamin D (Soliman et al., 2008). The authors found that the growth rates and height of the children increased with vitamin D supplementation, and that there was a significant correlation between serum concentrations of IGF-1 and the percentage increment in 25(OH)D concentrations, with IGF-1 concentrations increasing significantly after treatment with vitamin D. Both the length and the growth rate correlated with the IGF-1 concentration, leading the authors to conclude that the growth spurt observed in children with rickets after vitamin D supplementation is mediated via an increase in IGF-1 (Soliman et al., 2008).
polymorphism on fat-free mass or sarcopenia in elderly men.

**Non-genomic effects of vitamin D on muscle**

A pathway of vitamin D action, independent of the intra-nuclear transcription process, was mooted in the 1980s and has been characterized more recently (Boland et al., 1995; Nguyen et al., 2004). 1,25(OH)2D has been shown to be involved in the rapid regulation of membrane calcium channels in cultured chick skeletal muscle cells (Vazquez et al., 1997). Subsequently, a membrane receptor in rat chondrocytes with a higher molecular weight than the intra-nuclear VDR (known as the membrane-associated rapid response steroid-binding protein (MARRS) (Fleet, 2004), specific for 1,25(OH)2D, has been identified (Nemere et al., 1998). Recent evidence illustrating that the application of 1,25(OH)2D results in the translocation of the VDR to the plasma membrane in chick skeletal muscle cells (Capiati et al., 2002) and that the rapid effects of vitamin D require the VDR (Nguyen et al., 2004) suggests that a combination of both the intra-nuclear VDR and other membrane receptors (i.e., MARRS) may be involved in the rapid actions of vitamin D (Capiati et al., 2002). While the exact mechanism of the non-genomic action of vitamin D remains a controversial and heavily researched topic, it is widely accepted that vitamin D levels have a rapid effect on the membrane calcium channels of muscle cells in numerous species (Schmidt et al., 2000; Fleet, 2004; Nguyen et al., 2004). As calcium is a critical modulator of skeletal muscle function (Berchtold et al., 2000), it follows that vitamin D levels may have a significant impact on muscle function, performance and injury risk.

**Conclusion**

Vitamin D deficiency has traditionally been considered the domain of the elderly; however, this is changing as evidence of high rates of vitamin D deficiency is recognized in today’s youth. Vitamin D deficiency is now endemic in many communities and athletes are not spared this condition. Increasingly, vitamin D deficiency is recognized as being associated with both chronic health conditions and musculo-skeletal injuries such as stress fractures; however, its potential impact on other tissues such as muscle is not well described.

The identification of the VDR, its various polymorphisms, and variable expression with aging, has provided some insight into the complex mechanisms by which vitamin D and its metabolic pathways may affect muscle function. The recognition of both genomic and non-genomic effects of vitamin D in skeletal muscle, with the resultant impact on both calcium metabolism and protein transcription, further illustrates the significance of vitamin D in muscle function. Further clarification of the complex role of the VDR in both muscle and other musculo-skeletal tissues is required.

Despite the limited evidence available at the time, athletes and trainers in the early 20th century believed that UVB radiation was beneficial to athletic performance. Accumulating evidence supports the existence of a functional role for vitamin D in skeletal muscle with potentially significant impacts on both the performance and injury profiles of young, otherwise healthy athletes. While further research is required to evaluate the level of vitamin D required for optimal muscular function, clinicians working with athletes should be aware of the broad impact of vitamin D deficiency on the athlete.

Vitamin D should no longer be considered only to have an impact on calcium metabolism and bone morphology, but should be recognized to have a broad impact on the organism as a whole. Further epidemiological and *in vitro* research into the potential impact of vitamin D deficiency on muscle function, morphology and performance in young athletic individuals is required.

**Key words:** IGF-1, injury, deficiency.

**Acknowledgements**

The author would like to acknowledge the support of Dr. Justin Grantham, Professor Bengt Saltin and Dr. Hakim Chalabi in the preparation of this manuscript. In addition, the support of Ivana Matic and Tanya Hamilton is much appreciated.

The author has no financial or other conflicts of interest in the preparation of this manuscript.

**References**

Adams G. Insulin-like growth factor in muscle growth and its potential abuse by athletes. Br J Sports Med 2000: 34 (6): 412–413.

Allali F, El Aichaoui S, Saoud B, Maaroufi H, Abouqal R, Hajjaj-Hassouni N. The impact of clothing style on bone mineral density among post menopausal women in Morocco: a case-control study. Biomed Central Public Health 2006: 6: 1–6.

Allen R, Cureton T. Effects of ultraviolet radiation on physical fitness. Arch Phys Med 1945: 26: 641–644.

Andersen R, Molgaard C, Skovgaard L, Brot C, Cashman K, Chabros E, Charzew ska J, Flynn A, Jakobsen J,
Bischoff-Ferrari H, Dawson-Hughes B. Where do we stand on vitamin D? Bone 2007: 41: S13–S19.
Bischoff-Ferrari H, Dawson-Hughes B, Willett W, Stuehelin H, Bazemore M, Zee R, Wong J. Effect of vitamin D on falls: a meta-analysis. JAMA 2004b: 291(16): 1999–2006.
Bischoff-Ferrari H, Dietrich T, Orav E, hu F, Zhang Y, Karlson E, Dawson-Hughes B. Higher 25-hydroxyvitamin D concentration are associated with lower lower-extremity function in both active and inactive persons aged >60y. Am J Clin Nutr 2004a: 80: 752–758.
Bischoff-Ferrari H, Giovannucci E, Willett W, Dietrich T, Dawson-Hughes B. Estimation of optimal serum concentrations of 25-hydroxyvitamin D for multiple health outcomes. Am J Clin Nutr 2006: 84: 18–28.
Boland R, de Boland A, Marinissen M, Santillan G, Vazquez G, Zanello S. Avian muscle cells as targets for the secosteroid hormone 1,25-dihydroxy-vitamin D3. Mol Cell Endocrinol 1995: 114: 1–8.
Bray M, Hagberg JM, Perusse L, Rankinen T, Roth S, Wofarh B, Bouchard C. The human gene map for performance and health-related fitness phenotypes: the 2006–2007 update. Med Sci Sports Exerc 2009: 41: 34–72.
Broe K, Chen T, Weinberg J, Bischoff-Ferrari H, Holick M, Kiel D. A higher dose of vitamin D reduces the risk of falls in nursing home residents: a randomized, multiple-dose study. J Am Geriatr Soc 2007: 55(2): 234–239.
Bunout D, Barrera G, Leiva L, Gattas V, Pia de la Maza M, Avendano M, Hirsch S. Effects of vitamin D supplementation and exercise training on physical performance in Chilean vitamin D deficient elderly subjects. Exp Gerontol 2006: 41: 746–752.
Cannell J, Hollis B, Sorenson M, Taft T, Anderson J. Athletic performance and vitamin D. Med Sci Sports Exerc 2009: 41: 1101–1106.
Capiati D, Benassati S, Boland R. 1,25(OH)2-vitamin D3 induces translocation of the vitamin D receptor (VDR) to the plasma membrane in skeletal muscle cells. J Cell Biochem 2002: 86: 128–135.
Cashman K. Vitamin D in childhood and adolescence. Postgrad Med J 2007: 83: 230–235.
Ceglia L. Vitamin D and skeletal muscle tissue and function. Mol Aspects Med 2008: 29: 407–414.
Dawson-Hughes B, Heaney R, Holick M, Lips P, Meunier P, Vieth R. Estimates of optimal vitamin D status. Osteoporos Int 2005: 16: 713–716.
Dhesi J, Jackson S, Bearne L, Moniz C, Hurley M, Swift C, Allain T. Vitamin D supplementation improves neuromuscular function in older people who fall. Age Ageing 2004: 33: 589–595.
Dietrich T, Joshipura K, Dawson-Hughes B, Bischoff-Ferrari H. Association between serum concentrations of 25-hydroxyvitamin D3 and periodontal disease in the US population. Am J Clin Nutr 2004: 80: 108–113.
El-Hajj G, Nabulsi M, Tamim H, Maalouf J, Salamoun M, Khalife H, Choucair M, Arabi A, Vieth R. Effect of vitamin D replacement on musculoskeletal parameters in school children: a randomized controlled trial. J Clin End Met 2006: 91: 405–412.
Endo I, Inoue D, Mitsui T, Umaki Y, Akaike M, Youshizawa T, Kato S, Matsumoto T. Deletion of vitamin D receptor gene in mice results in abnormal skeletal muscle development with deregulated expression of myoregulatory transcription factors. Endocrinology 2003: 144: 5138–5144.
Fleet J. Rapid, membrane-initiated actions of 1,25 dihydroxyvitamin D: what are they and what do they mean? J Nutr 2004: 134: 3215–3218.
Floyd F, Ayyar D, Barwick D, Hudson P, Weightman D. Myopathy in chronic renal failure. Q J Med 1974: XLIII: 509–524.
Fonseca V, Tongria R, El-Hazmi M, Abu-Aisha H. Exposure to sunlight and vitamin D deficiency in Saudi Arabian women. Postgrad Med J 1984: 60: 589–591.
Garland C, Garland F, Gorham E, Lipkin M, Newmark H, Mohr S, Holick M. The role of vitamin D in cancer prevention. Am J Public Health 2006: 96: 252–261.
Gerdhem P, Ringsberg K, Obrant K, Akesson K. Association between 25-hydroxy vitamin D levels, physical activity, muscle strength and fractures in the prospective population-based OPRA Study of Elderly Women. Osteoporos Int 2005: 16: 1425–1431.
Geusens P, Vandeeyver C, Vanhoof J, Cassimian J, Boonen S, Raus J. Quadriceps and grip strength are related to vitamin D receptor genotype in elderly nonobese women. J Bone Miner Res 1997: 12: 2082–2088.
Giovannucci E, Liu Y, Rimm E, Hollis B, Fuchs C, Stampfer M, Willett W. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst 2006: 98: 451–459.
Glerup H, Mikkelsen P, Poulsen L, hass E, Overbeck S, Andersen h, Charles P, Eriksen E. Hypovitaminosis D myopathy without biochemical signs of osteomalacic bone involvement. Calcif Tissue Intl 2000: 66: 419–424.
Goldspink G. Changes in muscle mass and phenotype and the expression of autocrine and systemic growth factors by muscle in response to stretch and overload. J Anat 1999: 194: 323–334.

Goldspink G. Research on mechano growth factor: its potential for optimising physical training as well as misuse in doping. Br J Sports Med 2005: 39: 787–788.

Gordon C, DePeter K, Feldman H, Grace E, Emans S. Prevalence of vitamin D deficiency among healthy adolescents. Arch Pediatr Adolesc Med 2004: 158: 531–537.

Grounds M. Reasons for the degeneration of ageing skeletal muscle: a central role for IGFR-1 signalling. Biogerontology 2002: 3: 19–24.

Grundberg E, Brandstrom H, Ribom E, Ljunggren O, Mallmin H, Kindmark A. Genetic variation in the human vitamin D receptor is associated with muscle strength, fat mass and body weight in Swedish women. Eur J Endocrinol 2004: 150: 323–328.

Guo S, Magnuson V, Schiller J, Wang X, Wu Y, Ghosh S. Meta-analysis of vitamin D receptor polymorphisms and type 1 diabetes: a HuGE review of genetic association studies. Am J Epidemiol 2006: 164: 711–724.

Hannan MT, Litman HJ, Araujo AB, McNlenn CE, McLean RR, McKinlay JB, Jen TC, Holick MF. Serum 25-hydroxyvitamin D and bone mineral density in a racially and ethnically diverse group of men. J Clin Endocrinol Met 2007: 92: 2017–2019.

Hansen K, Jones A, Lindstrom M, Davis L, Engelke J, Shafer M. Vitamin D insufficiency: disease or no disease? J Bone Miner Res 2008: 23: 1052–1060.

Hashemipour S, Larijani B, Adibi H, Javadi E, Sadeghat M, Pajouhi M, Soltani A, Shafael A, Hamidi Z, Fard A, Hossein-Nezhad A, Booya F. Vitamin D deficiency and causative factors in the population of Tehran. BMC Public Health 2004: 4: 38–44.

Hatun S, Islam O, Cizmecioglu F, Kara B, Babaoglu K, Berk F, Gokalp A. Subclinical vitamin D deficiency is increased in adolescent girls who wear concealing clothing. J Nutr 2005: 135: 218–222.

Hoberman J. Faster, higher, stronger. A history of doping in sport. Bookfaster, 2002: 218–222.

Holick M. Vitamin D: importance in the prevention of cancers, type 1 diabetes, heart disease, and osteoporosis. Am J Clin Nutr 2004: 79: 362–371.

Holick M. High prevalence of vitamin D inadequacy and implications for health. Mayo Clin Proc 2006: 81: 353–373.

Holick M. Vitamin D deficiency. New Engl J Med 2007: 357: 266–281.

Hopkinson N, Li K, Kehoe A, Humphries S, Roughton M, Moxpath J, Montgomery H, Polkey M. Vitamin D receptor genotypes influence quadriceps strength in obstructive pulmonary disease. Am J Clin Nutr 2008: 87: 385–390.

Houston D, Cesari M, Ferrucci L, Cherubini A, Maggio D, Bartali B, Johnson M, Schwartz G, Kritchevsky S. Association between vitamin D status and physical performance: the InCHIANTI study. J Gerontol 2007: 62A: 440–446.

Hypponen E, Boucher B, Berry D, Power C. 25-hydroxyvitamin D, IGF-1, and metabolic syndrome at 45 years of age. Diabetes 2008: 57: 298–305.

Hypponen E, Laara E, Reunanen A, Jarvelin M, Virtanen S. Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001: 358: 1500–1503.

Iannuzzi-Sucich M, Prestwok J, Kenny A. Prevalence of saracopenia and predictors of skeletal muscle mass in healthy, older men and women. J Gerontol 2002: 57A: M772–M777.

Iranii P. Electromyography in nutritional osteomalacia myopathy. J Neurol Neurosurg Psychiatry 1976: 39: 686–693.

Jansen H, Samson M, Verhaar H. Vitamin D deficiency, muscle function, and falls in elderly people. Am J Clin Nutr 2002: 75: 611–615.

Lappe J, Cullen D, Haynatzki G, Recker R, Ahlrf R, Thompson K. Calcium and vitamin D supplementation decreases incidence of stress fractures in female navy recruits. J Bone Miner Res 2008: 23: 741–749.

Lappe J, Travers-Gastafson D, Davies K, Recker R, Heaney R. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr 2007: 85: 1586–1591.

Latham N, Anderson C, Lee A, Bennett D, Moseley A, Cameron I. A randomized, controlled trial of quadriceps resistance exercise and vitamin D in frail older people: the frailty interventions trial in elderly subjects (FITNESS). J Am Geriatr Soc 2003a: 51: 291–299.

Latham N, Anderson C, Reid I. Effects of vitamin D supplementation on strength, physical performance, and falls in older persons: a systematic review. J Am Geriatr Soc 2003b: 51: 1219–1226.

Liao L, Chen X, Wang S, Parlow A, Xu J. Identification of a functional vitamin D receptor localisation, in the HL-1 autocrine and systemic growth factors. Mol Endocrinol 2004: 18: 2460–2469.

Lovell G. Vitamin D status of females in an elite gymnastics program. Clinical J Sport Med 2008: 18: 159–161.

Malabanan A, Veronikis I, Holick M. Redefining vitamin D insufficiency. Lancet 1998: 351: 805–806.

Mingrone G, Greco A, Castagneto M, Gasbarrini G. A woman who left her wheelchair. Lancet 1999: 353: 806.

Mow E, Haug E, Bohm T. Low serum calciold concentration in older adults with reduced muscular function. J Am Geriatr Soc 1999: 47: 220–226.

Nemere I, Schwartz Z, Pedrozo H, Sylvia V, Dean D, Boyan B. Identifies an of a membrane receptor for 1,25-dihydroxyvitamin D3 which mediates rapid activation of protein kinase C. J Bone Miner Res 1998: 13: 1353–1359.

Nguyen T, Lieberherr M, Fritsch J, Guillozo H, Alvarez M, Fitouri Z, Jehan F, Garabedian M. The rapid effects of 1,25-dihydroxyvitamin D3 require the vitamin D receptor and influence 24-hydroxylase activity. J Biol Chem 2004: 279: 7591–7597.

Nibbelink K, Tishkoff D, Hershey S, Rahman A, Simpson R. 1,25(OH)2vitamin D actions on cell proliferation, size, gene expression, and receptor localisation, in the HL-1 cardiac myocyte. J Steroid Biochem Mol Biol 2007: 103: 533–537.

Nowson CA, Margerison C. Vitamin D intake and vitamin D status of Australians. Med J Aust 2002: 177: 149–152.

Pani M, Knapp M, Donner H, Braun J, Baur M, Usadel K, Badenhoop K. Vitamin D receptor allele combinations influence genetic susceptibility to type 1 diabetes in Germans. Diabetes 2000: 49: 504–507.

Peng L, Malloy P, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Mol Endocrinol 2004: 18: 1109–1119.

Pfeifer M, Begerow B, Minne H. Vitamin D and muscle function. Osteoporos Int 2002: 13: 187–194.

Pittas A, Lau J, Hu F, Dawson-Hughes B. The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis. J Clin Endocrinol Met 2007: 92: 2017–2019.

Prabhala A, Garg R, Dandona P. Severe myopathy associated with vitamin D deficiency in Western New York. Arch Intern Med 2000: 160: 1199–1203.

Rabon-Stith K, Hagberg J, Phares D, Kostek M, Delmonico M, Roth S, Ferrell R, Conway J, Ryan A, Hurley
B. Vitamin D receptor FokI genotype influences bone mineral density response to strength training, but not aerobic training. Exp Physiol 2005: 90: 653–661.

Rimaniol J, Authier F, Chariot P. Muscle weakness in intensive care patients: initial manifestation of vitamin D deficiency. Intensive Care Med 1994: 20: 591–592.

Rockell J, Green T, Skeaff C, Whiting S, Taylor RR, Williams S, Parnell W, Scragg R, Wilson N, Schaaf D, Fitzgerald E, Wohlers M. Season and ethnicity are determinants of serum 25-hydroxyvitamin D concentrations in New Zealand children aged 5–15 y. J Nutr 2005: 135: 2602–2608.

Roth S, Zmuda J, Cauley J, Shea P, Ferrell R. Vitamin D receptor genotype is associated with fat-free mass and sarcopenia in elderly men. J Gerontol 2004: 59A: 10–15.

Schertzer J, Gehrig S, Ryall J, Lynch GS. Modulation of insulin-like growth factor (IGF-1) and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Am J Pathol 2007: 171: 1180–1188.

Schmidt B, Gerdes D, Feuring M, Falkenstein E, Christ M, Wehling M. Rapid, nongenomic steroid actions: a new age? Front Neuroendocrinol 2000: 21: 57–94.

Simpson R, Thomas G, Arnold A. Identification of 1,25-dihydroxy-vitamin D₃ receptors and activities in muscle. J Biol Chem 1985: 260: 8882–8891.

Solinan A, Al Khalaf F, Alhemandi N, Al Ali M, Al Zayoud M, Yakoot K. Linear growth in relation to the circulating concentrations of insulin-like growth factor 1, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism 2008: 57: 95–102.

Tajima O, Ashizawa N, Ishii T, Amagai H, Mashimo T, Liu L, Saitoh S, Tokuyama K, Suzuki M. Interaction of the effects between vitamin D receptor polymorphism and exercise training on bone metabolism. J Appl Physiol 2000: 88: 1271–1276.

Thissen J-P, Ketelslegers J-M. Underwood L. Nutritional regulation of the insulin-like growth factors. Endocr Rev 1994: 15: 80–101.

Vazquez G, de Boland A, Boland R. Stimulation of Ca²⁺ release-activated Ca²⁺ channels as a potential mechanism involved in non-genomic 1,25(OH)₂-vitamin D₃-induced Ca²⁺ entry in skeletal muscle cells. Biochem Biophys Res Com 1997: 239: 562–565.

Verhaar H, Samson M, Jansen P, de Vreede P, Manten J, Duursma S. Muscle strength, functional mobility and vitamin D in older women. Aging Clin Exp Res 2000: 12: 455–460.

Visser M, Deeg D, Lips P. Low vitamin D and high parathyroid hormone levels as determinants of loss of muscle strength and muscle mass (sarcopenia): the longitudinal aging study Amsterdam. J Clin Endocrinol Metab 2003: 88: 5766–5772.

Ward K, Das G, Berry J, Roberts S, Rawer R, Adams J, Mughal Z. Vitamin D status and muscle function in postmenarchal adolescent girls. J Clin Endocrinol Metab 2009: 94: 559–563.

Wassner S, Li J, Sperduto A, Norman M. Vitamin D deficiency, hypocalcemia, and increased skeletal muscle degradation in rats. J Clin Invest 1983: 72: 102–112.

Wicherts I, van Schoor N, Boeke J, Visser M, Deeg D, Smit J, Knol D, Lips P. Vitamin D status predicts physical performance and its decline in older persons. J Clin Endocrinol Metab 2007: 92: 2058–2065.

Zhang C, Wang C, Liang J, Zhou X, Zheng F, Fan Y, Shi Q. The vitamin D receptor FokI polymorphism and bone mineral density in Chinese children. Clin Chim Acta 2008: 395: 111–114.

Ziambaras K, Dagogo-Jack S. Reversible muscle weakness in patients with vitamin D deficiency. West J Med 1997: 167: 435–439.